Eli Lilly and Company has announced plans to start the rollout of its Tempo Personalized Diabetes Management Platform in the US later this year.
The new platform has been designed to help clinicians and adult patients with type 1 or type 2 diabetes make data-backed decisions for managing treatment with Lilly insulins.
Go deeper with GlobalData
It includes TempoSmart, a compatible app; Tempo Pen, a prefilled insulin pen; and the Tempo Smart Button.
Lilly stated that the three components combine to provide personalised guidance for adults with diabetes.
The reusable Tempo Smart Button attaches to the top of the Tempo Pen, the company’s prefilled, disposable pens that were approved in 2019 and 2020.
See Also:
The smart button detects, stores and transfers insulin dose-related data to the compatible app through Bluetooth technology.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe TempoSmart app records the insulin dose data and also enables data sharing between patients and healthcare providers.
Through the TempoSmart app, patients can access their insulin dose information and receive medication reminders, personalised education resources and feedback on their blood glucose levels.
The app also enables Integration with Dexcom Continuous Glucose Monitoring (CGM) Systems, the Tempo Blood Glucose Monitor (BGM) and other compatible BGMs.
It is also compatible with wearable devices such as Google Fit, Fitbit, Garmin and the Apple Health app, and is able to share data with them.
Lilly Diabetes connected care head Kevin Cammack said: “Launching this platform is an opportunity for us to more broadly support those who rely on our insulins.
“Despite technological advancements, people continue to experience challenges with the complexities of insulin dosing.
“Using the learnings from early adopters of Tempo, we look forward to continually innovating our technology to aid those who use Lilly insulins to manage their diabetes.”
The company intends to begin a staged rollout of the platform to a few clinics later this year, with a nationwide launch expected next year.
